{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:33:15Z","timestamp":1791415995827,"version":"4.3.3"},"reference-count":31,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2010,5,13]],"date-time":"2010-05-13T00:00:00Z","timestamp":1273708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2010,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Epidemiological studies related to hospitalization due to the hepatotoxicity of traditional non\u2010steroidal anti\u2010inflammatory drugs (NSAIDs) are infrequent, and case reports of hepatotoxicity of nimesulide, celecoxib, and rofecoxib seem to be increasing. The reimbursement database of National Health Insurance (NHI) in Taiwan provided an opportunity for post\u2010marketing surveillance. We conducted this study to determine the association between the use of hepatoxic NSAIDs and increased hospitalizations related to acute hepatitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We included hospitalized subjects with a major diagnosis of acute or sub\u2010acute necrosis of liver or toxic hepatitis and excluded viral and other causes of hepatobiliary diseases from the NHI database from 1 April 2001 to 31 December 2004. We applied two kinds of models to analyze by uni\u2010directional and bi\u2010directional case\u2010crossover designs during the 28 days exposure periods and performed conditional logistic regression models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 4519 cases of hospitalization relating to acute hepatitis, and the odds ratios of celecoxib, nimesulide, dicofenac, ibuprofen, and other hepatoxic NSAIDs were significantly increased. Compared with the adjusted odds ratios of other hepatoxic NSAIDs (OR\u2009=\u20092.13, 95%CI\u2009=\u20092.00, 2.28), celecoxib (OR =1.92, 95%CI\u2009=\u20091.38, 2.69) was similar during the 28 days by our uni\u2010directional case\u2010crossover design.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our results provide evidence for an increased risk of hospitalization with acute hepatitis among hepatoxic NSAIDs including celecoxib users. Further mechanistic research is warranted in order to document celecoxib's hepatotoxicity. Copyright \u00a9 2010 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.1966","type":"journal-article","created":{"date-parts":[[2010,5,13]],"date-time":"2010-05-13T10:06:59Z","timestamp":1273745219000},"page":"708-714","source":"Crossref","is-referenced-by-count":34,"title":["Increased risk of hospitalization for acute hepatitis in patients with previous exposure to NSAIDs"],"prefix":"10.1002","volume":"19","author":[{"given":"Chang\u2010Hsing","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung\u2010Der","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau\u2010Chung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,6,25]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-12-200212170-00007"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0009-9236(95)90078-0"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.34857"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-30105"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.02092.x"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(98)80188-8"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280100312"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(00)80208-1"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.4.553"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-134-3-200102060-00028"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.323.7303.23"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/pmj.77.910.548"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2003.09.006"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(02)00177-0"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00045391-200007030-00003"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7405.18"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.08.014"},{"key":"e_1_2_7_19_2","unstructured":"Department of Health.Health and national health insurance annual statistics in Taiwan. Available at:http:\/\/www.doh.gov.tw\/statistic\/index.htmaccessed [1 November 2008]."},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a115853"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1557(199710)6:3 <S51::AID-PDS301>3.0.CO;2-S"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.2307\/3109766"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.publhealth.21.1.193"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8278(90)90124-A"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(93)90101-6"},{"key":"e_1_2_7_26_2","volume-title":"Micromedex\u00ae 1.0 Healthcare Series [Internet database]"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.08.002"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2008.05511.x"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00045391-200205000-00005"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00777-3"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(97)80492-8"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1750"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1966","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.1966","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T15:46:52Z","timestamp":1700581612000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.1966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,25]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["10.1002\/pds.1966"],"URL":"https:\/\/doi.org\/10.1002\/pds.1966","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,25]]}}}